Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Algunas Inc., dba Woodland Hills Compounding Pharmacy
483
•Algunas Inc., dba Woodland Hills Compounding Pharmacy•April 29, 2016

Algunas Inc., dba Woodland Hills Compounding Pharmacy – FDA 483, Apr 29, 2016

Record Details

During an FDA inspection from April 25-29, 2016, Algunas Inc., operating as Woodland Hills Compounding Pharmacy, was cited for several significant quality control deficiencies. The inspection, documented in an FDA 483, identified three main observations indicating non-compliance with manufacturing regulations. Firstly, the pharmacy's procedures for handling drug product complaints and adverse drug events were found to be inadequate. There was no systematic review or maintenance of complaint files, and employee training procedures did not require reporting of adverse events or documentation of communications with medical providers or patients. Secondly, the firm failed to thoroughly investigate unexplained discrepancies and batches that did not meet specifications. They lacked a formal procedure for investigating failed batches, did not maintain a log of such incidents, and often omitted root-cause analyses. Furthermore, the pharmacy utilized non-validated test methods from a third-party laboratory for critical drug product potency testing. Finally, observations highlighted issues with equipment calibration. A pH meter lacked independent calibration and proper controls for temperature variation, and its calibration records were not logged for trend monitoring. An expired calibration standard was also in use. These observations underscore the necessity for Woodland Hills Compounding Pharmacy to implement comprehensive corrective actions to ensure adherence to regulatory standards for drug manufacturing.

Company
Algunas Inc., dba Woodland Hills Compounding Pharmacy
Inspection date
April 29, 2016
Product type
Drugs
Office
Los Angeles District Office
Person
  • Roger F. Zabinski (Investigator)
View Company Profile

ID · 9d762d2f-1899-48d1-88e6-e77a9e173fcd

Violation Codes4
21 U.S.C. 324(a)(4)21 CFR 211.19221 CFR 331(c)FD&C Act 901(a)(1)

Full citation text and observation details available on the Dashboard.

Other documents for Algunas Inc., dba Woodland Hills Compounding Pharmacy
  • 483 - 2018-10-11October 11, 2018
  • WARNING_LETTER - 2016-04-29April 29, 2016

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Algunas Inc., dba Woodland Hills Compounding Pharmacy
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.